BiopharmIQ by Amp

🤖 𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 (𝐀𝐈) 𝐢𝐬 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐛𝐢𝐨/𝐩𝐡𝐚𝐫𝐦𝐚 𝐭𝐞𝐜𝐡 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 What percent of bio/pharma companies are emphasizing AI in their tech development? We attempted answer this question using our biopharmIQ corporate intelligence platform* 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 ~9% of the biopharmIQ companies on our platform emphasize AI in their tech 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐲𝐩𝐞 ⇒ Not surprising, computational biology (~39%) companies lead the way ⇒ Diagnostics companies (~25%) are beating bio/pharma and their vendors 𝐂𝐨𝐮𝐧𝐭𝐫𝐲 ⇒ From a country perspective, Israel (17%) is leading the way followed by the UK (~12%) 𝐒𝐭𝐚𝐭𝐞 ⇒ From a state perspective in the U.S., Washington leads the way (~13%) ⇒ On the other end, only ~5% of the bio/pharma companies from New Jersey emphasize AI for their tech 𝐌𝐞𝐭𝐡𝐨𝐝 *We used AI to upgrade the technology descriptions in our biopharmIQ database, and then analyzed those descriptions to determine the current prevalence of AI in bio/pharma tech 𝐋𝐞𝐚𝐫𝐧 𝐌𝐨𝐫𝐞 🤔 Want to learn more? Want to search the ~10,000 bio/pharma tech descriptions yourself? https://lnkd.in/g_QTJQQK

November PDUFA Update: 4 Approvals and 1 AdComm We found these using our free PDUFA calendar on biopharmIQ: https://lnkd.in/gYjz8QkR See summary for more details on recent FDA decisions & upcoming PDUFA/Adcom events this month.👇 📌 This Week’s AdCom & PDUFA decision: AstraZeneca (NASDAQ: AZN) ⇨ Andexxa (coagulation factor Xa) ‣ Life-threatening or uncontrolled bleeding ‣ Adcom: 11/21/24 (sBLA) Jazz Pharmaceuticals (NASDAQ: JAZZ) & Zymeworks Inc. (NASDAQ: ZYME): Approved 11/20 ✅ ⇨ Ziihera (zanidatamab) ‣ HER2-positive biliary tract cancer  ‣ PDUFA: 12/29/24 (BLA) 🗓️ Previous Weeks’ PDUFA decisions: Syndax Pharmaceuticals (NASDAQ: SNDX): Approved 11/15 ✅ ⇨ Revuforj® (revumenib) ‣ Adult and Pediatric R/r Acute Leukemia ‣ PDUFA: 12/26/24 (NDA) PTC Therapeutics, Inc. (NASDAQ: PTCT): Approved 11/13 ✅ ⇨ KEBILIDI™ (eladocagene exuparvovec)  ‣ AADC deficiency    ‣ PDUFA: 11/13/24 (BLA) Journey Medical Corporation (NASDAQ: DERM): Approved 11/4 ✅ ⇨ Emrosi™ (Minocycline HCl Extended Release Capsules 40mg) ‣ Rosacea ‣ PDUFA: 11/4/24 (NDA) 📣 PDUFAs in Upcoming Weeks:  Applied Therapeutics, Inc. (NASDAQ: APLT) ‣ Govorestat BridgeBio (NASDAQ: BBIO) ‣ Acoramidis Check out the table below 📸👇 and our free blog post for details about each of these: https://lnkd.in/gcZg5CFZ PDUFA and clin trial readouts are part of our powerful, affordable online platform: https://lnkd.in/gYjz8QkR ❓ Have questions or want to schedule an online demo?  Contact marketing@biopharmiq.com   Check out also the November PDUFA calendar below. 📸 👇

🔍 Find your target companies fast using our AI-powered platform 1. Just type the technology(s) of your target companies into our easy-to-use form* (no email or log-in required):  https://lnkd.in/gWTR6JV9 2. Our Artificial Intelligence (AI) - powered platform: ⇒ Searches for your search terms, in the technology descriptions of ~10K bio/pharma companies that we generated using AI ⇒ And presents a list of your target companies to you in seconds 💡 Want to learn more about all our platform's features? Send us an LI message, and we'll schedule an online demo ASAP! *Our search is Boolean-enabled for more power

💰 2024 Q1-Q3 Late Stage Funded Biotech Companies We analyzed late-stage* biotech funding data from our online biopharmIQ platform for Q1-Q3 2024, focusing on geographic distribution. See our blog post for details: https://lnkd.in/g6rEmde3 💡 Not surprisingly, the leading states were: ⇒ California (56 companies) ⇒ Massachusetts (39 companies) 🤔 Surprising? ⇒ New York (10 comp) came in 3rd ⇒ As many as NJ (5), NC (3), and MD (2) combined For more details and more graphical data, see our blog post: https://lnkd.in/gEp97rrE Have questions or want to schedule an online demo? Contact marketing@biopharmIQ.com. *Late stage = Series B, C, D, E and debt financing

💰 Prospect Recently Funded Bio/Pharma Companies in 5 Steps It's no secret that recently funded companies are looking to spend in meaningful ways. To increase revenue and/or continue to develop their own products. They are actively looking for tools/services like yours that help them with the above. 🤔 But how do you find these companies without wasting tons of time? biopharmIQ tracks funding activity daily so you can easily know when your ideal partner is looking for your product/service. Here are 5 simple steps to prospect your recently funded target customers 🎥: https://lnkd.in/gdv4EzfN

💰 Prospect Recently Funded Companies in 5 Steps It's no secret that recently funded companies are looking to spend in meaningful ways. To increase revenue and/or continue to develop their own products. They are actively looking for tools/services like yours that help them with the above. 🤔 But how do you find these companies without wasting tons of time? biopharmIQ tracks funding activity daily so you can easily know when your ideal partner is looking for your product/service. Here are 5 simple steps to prospect your recently funded target customers 🎥: https://lnkd.in/gdv4EzfN

🎯 6 biopharma companies FDA PDUFA dates by the end of November. We found these using our free PDUFA calendar on biopharmIQ: https://lnkd.in/gYjz8QkR Iterum Therapeutics plc PDUFA date: October 25, 2024 Journey Medical Corporation PDUFA date: November 4, 2024 Autolus Therapeutics PDUFA date: November 16, 2024 Applied Therapeutics, Inc. PDUFA date: November 28, 2024 BridgeBio PDUFA date: November 29, 2024 Zymeworks Inc. PDUFA date: November 29, 2024 Check out the table below 📸👇 and our free blog post for details about each of these: https://lnkd.in/g72yvSJy PDUFA and clin trial readouts are part of our powerful, affordable online platform: https://lnkd.in/gbQqpw9g ❓ Have questions or want to schedule an online demo? Contact marketing@biopharmiq.com

💰 16 New/Emerging Cell & Gene Therapy (CGT) Companies in Q1-Q3 2024 Our team adds new/emerging biotech companies and new funding events to our online biopharmIQ platform every day. We found 16 in Q1-Q3 2024 (see graphic). Sign up for a free account on our platform to learn more about these companies, and to set up a notification to be alerted any time a new CGT company emerges or gets funded: https://lnkd.in/gKuAJFaC 📊 We analyzed our data on the 16 new/emerging CGT companies we identified in Q1-Q3 2024: All 16 raised >$1M 7 Gene Tx 6 Cell Tx 2 Gene Editing/CRSPR 1 RNA Tx For more details re: new/emerging CGT companies in Q1-Q3 2024, see our blog post on our biopharmIQ web page. ❓ Have questions or want to schedule an online demo? Contact marketing@biopharmIQ.com

It's great to see new significant cell and gene therapy companies continue to emerge in 2024. You can check out bio/pharma funding data yourself for free, and even create an email alert any time a new bio/pharma company that meets your search criteria emerges from stealth or closes another round of funding by creating a free account on biopharmIQ.com. It's helpful data as various state and local governments, organizations, and many universities try to spawn more bio/pharma commercial opportunities. Is/should a goal of those local and state groups be to have at least X new $1M+ funded bio/pharma company emerge from their territory every year or every X years? This data set of 3 quarters of 2024 may be too short for us to draw conclusions, but it's hard not to be impressed by 3 new >$1M bio/pharma start-ups in Washington. For NY, my bias is that many of the "start-ups" in NY the initial corporate shells raised by NY-based financial institutions that then set up shop in Boston or maybe make their way to San Fran, when they need biopharma employees? However, I believe the state of NY and/or the biotech community there, has invested a lot of money to further develop biotech in NY. Sounds like a smart idea to retain more of those companies in the local community. Gives me an idea for another future post for our biopharmIQ team to look at states with the most later stage funding activity.

💰 16 New/Emerging Cell & Gene Therapy (CGT) Companies in Q1-Q3 2024 Our team adds new/emerging biotech companies and new funding events to our online BiopharmIQ platform every day. See recent biotech funding activity: https://lnkd.in/g6rEmde3 We analyzed our data on the 16 new/emerging CGT companies we identified in Q1-Q3 2024: 14 were from the U.S. (See Graphic) 💡 Not surprisingly, the leading state was: ⇒ California (4 companies) 🤔 Surprising? Tied for 2nd ⇒ Washington (3 companies) ⇒ New York (3 companies) ⇒ WA and NY had more new CGT companies than Massachusetts (2 companies) For more details re: new/emerging CGT companies Q1-Q3 2024, see our blog post https://lnkd.in/gSNgsqzn ❓ Have questions or want to schedule an online demo? Contact marketing@biopharmIQ.com.